General News ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies EN June 11, 2019
General News Oxurion NV – Data from Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting EN June 6, 2019
News Regulated Transparency/Denominator Regulated information – Transparency Statement OXUR shares EN NL May 10, 2019
News Regulated Transparency/Denominator Regulated information – Transparency Statement Clay EN NL May 10, 2019
General News Oxurion NV announces full enrollment in Phase 1 trial evaluating the safety of plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule EN April 24, 2019
General News Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for the treatment of DME, ahead of schedule EN April 4, 2019
General News Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting EN February 28, 2019
General News Oxurion NV to Present at 2019 Biotech Showcase Conference and Participate in CEO Power Breakfast Roundtable during the 37th Annual J.P. Morgan Healthcare Conference EN December 19, 2018
General News Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD EN November 5, 2018
General News Oxurion NV Announces the Appointment of Adrienne Graves to its Board of Directors EN October 29, 2018
General News Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting EN October 24, 2018
General News Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project EN October 22, 2018
General News Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) EN September 20, 2018
General News Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) EN September 20, 2018
